Cotadutide, a dual GLP-1 and glucagon receptor (GCGR) agonist, has been reported to improve inflammation and fibrosis in NASH animals and this effect was stronger than that of liraglutide. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.